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EDITORIALDeciphering the Role of Mesenteric Fat in Inﬂammatory
Bowel Diseasewell-known feature of inﬂammatory bowel diseaseA(IBD), especially long-standing Crohn’s disease, is
mesenteric “creeping fat,” which wraps around the intestine.
Yet the role of such mesenteric fat in IBD pathophysiology
has remained relatively elusive. Some have hypothesized
that such fat might serve a protective role, possibly serving
to ameliorate disease or offer an additional level of pro-
tection in the face of mucosal injury. For example, one might
imagine that the wrapping fat might serve as a barrier to
bacteria that might have breached the intestinal mucosa.
Other investigators have proposed that mesenteric adipose
tissue might serve an anti-inﬂammatory role. In this issue of
Cellular and Molecular Gastroenterology and Hepatology,
Sideri et al1 report ﬁndings that indicate that mesenteric fat
may indeed normally be programmed to dampen inﬂam-
mation but has acquired a tendency to promote inﬂamma-
tion in IBD.
A major reason the role of creeping fat in IBD has
remained enigmatic is that its study is inherently difﬁcult.
Speciﬁcally, creeping fat generally does not exist in
healthy control subjects, which precludes the approach of
comparing disease versus control specimens that is
typically used in biomedical research. To surmount this
problem, Pothoulakis and colleagues isolated and
cultured premesenteric adipocytes from healthy in-
dividuals and those with IBD, including both Crohn’s
disease and ulcerative colitis (UC) patients. They
observed that, when isolated from healthy subjects,
the preadipocytes from the controls released readily
detectable levels of the anti-inﬂammatory cytokine
interleukin-10 (IL-10). In contrast, the preadipocytes
from IBD patients, both those with Crohn’s disease and
UC, released elevated levels of IL-1b and showed a dra-
matic elevation in the levels of IL-17, which were not
detectable in the preadipocytes from the controls.
They also studied how such cells responded to the
neurotransmitter substance P, which they have shown
has immune modulating properties and is present in
elevated levels in IBD. A striking disease-related pattern
of responsiveness was observed. Speciﬁcally, in control
preadipocytes, stimulation by substance P resulted in a
rapid reduction of expression of a number of proin-
ﬂammatory cytokines, including IL-17, tumor necrosis
factor-a, and interferon-g, suggesting that substance P
ligation of the substance P receptor on mesenteric adi-
pocytes might normally serve to dampen or prevent gut
inﬂammation. In contrast, in the preadipocytes from IBD
patients, substance P resulted in a rapid activation of
expression in proinﬂammatory cytokines as assessed atCellular and Molecular Gastroenterology and Hepatology 2015;1:352–3both the mRNA and protein levels. Interestingly, both
Crohn’s disease and UC displayed markedly distinct pat-
terns in the speciﬁc cytokines induced by substance P
with the singular exception that the elevations in IL-17
were common to both of these forms of IBD.
These ﬁndings are in accord with previous observa-
tions that elevations in IL-17 expression are a central
feature of IBD, but they suggest that creeping fat may not
be a beneﬁcial adaptation. Conversely, creeping fat
may be contributing to the immune dysregulation asso-
ciated with IBD. That the differential responsiveness of
control and disease-derived preadipocytes persisted
after multiple passages in cell culture suggests that
these are stable characteristics of such cells acquired as a
result of disease; alternatively, they could represent an
inherent alteration in the adipocyte cell signaling of IBD
patients.
The view that adipocytes are contributors to inﬂam-
mation has gained momentum among researchers
studying a number of diseases states, including cancer
and type 2 diabetes, both of which are thought to be
promoted by proinﬂammatory cytokines released by
these cells. Yet inﬂammation also promotes adipogenesis
as evidenced by the existence of creeping fat itself and
observations that low-grade inﬂammation can promote
increased adiposity. It will be important for future
studies to better understand how inﬂammation promotes
the generation of creeping fat and whether IL-17 and the
other cytokines that this tissue generates are driving
clinical manifestations of disease. Indeed, the recent
failure of antibody-mediated neutralization of IL-17 to
ameliorate Crohn’s disease cautions against the view that
adipocyte production of proinﬂammatory cytokines is
actually detrimental to the host. Nonetheless, thanks to
Pothoulakis and colleagues’ elegant study, we can at least
appreciate that mesenteric fat is certainly not an innocent
bystander in gut immunity and inﬂammation but rather is
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